Adipose-Derived Stromal Cells for Treatment of Patients with Chronic Ischemic Heart Disease (MyStromalCell Trial):A Randomized Placebo-Controlled Study by Qayyum, Abbas Ali et al.
u n i ve r s i t y  o f  co pe n h ag e n  
Københavns Universitet
Adipose-Derived Stromal Cells for Treatment of Patients with Chronic Ischemic Heart
Disease (MyStromalCell Trial)
Qayyum, Abbas Ali; Mathiasen, Anders Bruun; Mygind, Naja Dam; Kühl, Jørgen Tobias;
Jørgensen, Erik; Helqvist, Steffen; Elberg, Jens Jørgen; Kofoed, Klaus Fuglsang; Vejlstrup,
Niels Groove; Fischer-Nielsen, Anne; Haack-Sørensen, Mandana; Ekblond, Annette; Kastrup,
Jens
Published in:
Stem Cells International
DOI:
10.1155/2017/5237063
Publication date:
2017
Document version
Publisher's PDF, also known as Version of record
Document license:
CC BY
Citation for published version (APA):
Qayyum, A. A., Mathiasen, A. B., Mygind, N. D., Kühl, J. T., Jørgensen, E., Helqvist, S., ... Kastrup, J. (2017).
Adipose-Derived Stromal Cells for Treatment of Patients with Chronic Ischemic Heart Disease (MyStromalCell
Trial): A Randomized Placebo-Controlled Study. Stem Cells International, 2017, [5237063].
https://doi.org/10.1155/2017/5237063
Download date: 03. Feb. 2020
Clinical Study
Adipose-Derived Stromal Cells for Treatment of
Patients with Chronic Ischemic Heart Disease (MyStromalCell
Trial): A Randomized Placebo-Controlled Study
Abbas Ali Qayyum,1 Anders Bruun Mathiasen,1 Naja Dam Mygind,1 Jørgen Tobias Kühl,1
Erik Jørgensen,1 Steffen Helqvist,1 Jens Jørgen Elberg,2 Klaus Fuglsang Kofoed,1,3
Niels Groove Vejlstrup,1 Anne Fischer-Nielsen,4 Mandana Haack-Sørensen,5
Annette Ekblond,5 and Jens Kastrup1,5
1Department of Cardiology & Cardiac Catheterization Laboratory 2014, The Heart Centre, Rigshospitalet, University of Copenhagen,
Blegdamsvej 9, 2100 Copenhagen, Denmark
2Department of Plastic Surgery, Rigshospitalet, University of Copenhagen, Blegdamsvej 9, 2100 Copenhagen, Denmark
3Department of Radiology, Diagnostic Center, Rigshospitalet, University of Copenhagen, Blegdamsvej 9, 2100 Copenhagen, Denmark
4Department of Clinical Immunology, Rigshospitalet, University of Copenhagen, Blegdamsvej 9, 2100 Copenhagen, Denmark
5Cardiology Stem Cell Centre, The Heart Centre, Rigshospitalet, University of Copenhagen, Blegdamsvej 9,
2100 Copenhagen, Denmark
Correspondence should be addressed to Abbas Ali Qayyum; Abbas.Ali.Qayyum@regionh.dk
Received 23 June 2017; Revised 21 September 2017; Accepted 12 October 2017; Published 3 December 2017
Academic Editor: Wojtek Wojakowski
Copyright © 2017 Abbas Ali Qayyum et al. This is an open access article distributed under the Creative Commons Attribution
License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is
properly cited.
We aimed to evaluate the eﬀect of intramyocardial injections of autologous VEGF-A165-stimulated adipose-derived stromal cells
(ASCs) in patients with refractory angina. MyStromalCell trial is a randomized double-blind placebo-controlled study including
sixty patients with CCS/NYHA class II-III, left ventricular ejection fraction> 40%, and at least one signiﬁcant coronary artery
stenosis. Patients were treated with ASC or placebo in a 2 : 1 ratio. ASCs from the abdomen were culture expanded and
stimulated with VEGF-A165. At 6 months follow-up, bicycle exercise tolerance increased signiﬁcantly in time duration 22 s
(95%CI −164 to 208 s) (P = 0 034), in watt 4 (95%CI −33 to 41, 0.048), and in METs 0.2 (95%CI −1.4 to 1.8) (P = 0 048) in the
ASC group while there was a nonsigniﬁcant increase in the placebo group in time duration 9 s (95%CI −203 to 221 s) (P =
0 053), in watt 7 (95%CI −40 to 54) (P = 0 41), and in METs 0.1 (95%CI −1.7 to 1.9) (P = 0 757). The diﬀerence between
the groups was not signiﬁcant (P = 0 680, P = 0 608, and P = 0 720 for time duration, watt, and METs, resp.). Intramyocardial
delivered VEGF-A165-stimulated ASC treatment was safe but did not improve exercise capacity compared to placebo. However,
exercise capacity increased in the ASC but not in the placebo group. This trial is registered with ClinicalTrials.gov NCT01449032.
1. Introduction
Ischemic heart disease is one of the leading causes of prema-
ture death worldwide [1]. Due to improvements in medical
and interventional therapies at the acute and chronic stages
of ischemic heart disease, the years of life lived with chronic
ischemic heart disease (CIHD) have increased during the last
decades [2]. However, in spite of these improvements, a large
number of patients still suﬀer from refractory angina leading
to reduced work capacity and reduced quality-of-life due to
impaired myocardial perfusion. To improve myocardial
perfusion and thereby cardiac symptoms, stem cell therapy
is intensively investigated preclinically and clinically but
the optimal cell source has yet to be identiﬁed.
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Adipose tissue is of mesodermal origin and contains
multipotent adipose-derived stromal cells (ASCs), which
have the same potential for diﬀerentiation and regeneration
as bone marrow-derived mesenchymal stromal cells (MSCs)
[3–6]. Adipose tissue is available in larger quantities, and the
stromal vascular fraction (SVF) obtained contains a much
higher concentration of ASCs than MSCs from the bone
marrow [5, 7]. As compared to the highly heterogeneous cell
population in the SVF isolated immediately after liposuction
and used in studies as the Precise and Athena trials [8, 9], the
cell population obtained after culture expansion is almost
100% homogeneous ASC population. A higher concentration
of ASCs injected into patients with ischemic heart disease
may result in a more pronounced treatment [10–13]. ASCs
are reported to be more angiogeneic than MSCs, which
potentially favors myocardial perfusion and regeneration in
CIHD [14–16]. Furthermore, in vitro serum starvation and
vascular endothelial growth factor (VEGF) stimulation facil-
itate diﬀerentiation of both MSCs and ASCs towards endo-
thelial cell linage [17, 18]. Therefore, a clinical treatment
with ASCs primed towards endothelial cell lineage could
potentially be beneﬁcially in inducing angiogenesis.
The MyStromalCell trial is a follow-up to our previous
clinical trial, where patients with stable CIHD were treated
with equally prestimulated bone marrow MSCs [10].
So far, clinical treatment experience with adipose-derived
cells is limited to the adipose-derived SVF, and culture-
expanded ASCs have not been tested in patients with ische-
mic heart disease [8, 9, 19]. The aim of this randomized
double-blind placebo-controlled clinical trial was to investi-
gate the treatment eﬀects of intramyocardial delivered
VEGF-A165-stimulated culture-expanded ASCs in patients
with CIHD and refractory angina with preserved left ventri-
cle ejection fraction (LVEF)> 40%.
2. Methods
2.1. Study Design. MyStromalCell trial is a phase II, ﬁrst-in-
man, single-center, double-blind, randomized, placebo-
controlled study of intramyocardial injections of autologous
ASCs in patients with CIHD and refractory angina due to
at least one occluded or severely stenotic coronary artery
and preserved LVEF. This trial was initiated in 2010 and
the enrolment was completed in 2014. The study design has
been published previously [20].
The study protocol complies with the Declaration of
Helsinki and is approved by the Danish National Ethical
Committee (02-268856) and Danish Medicines Agency
(2612-2867). The study is registered at ClinicalTrials.gov
(NCT01449032). The Good Clinical Practice Unit of the
Capital Region monitored the study. All patients provided
written informed consent.
2.2. Study Population. Patients between 30 and 80 years of
age with CIHD and refractory angina due to at least one
signiﬁcantly stenosed coronary artery visualized on inva-
sive angiogram without any options for revascularization
were considered for inclusion. The patients had to have
ischemic symptoms despite optimal tolerable antianginal
medication and LVEF> 40%. Inclusion and exclusion criteria
are described in Appendix A and Appendix B. The patients
were tested on a maximal bicycle exercise tolerance test
(ETT) on which they had to stop due to ischemic heart
symptoms. Standard bicycle ETT was used, which is rec-
ommended by the Danish Society of Cardiology for the
detection of myocardial ischemia. The same protocol was
used by Friis et al. [10]. The patients had to cycle between
2 and 10min at baseline to ensure that their performance
status was not too poor or too good.
The patients were randomized 2 : 1 to ASC or placebo, in
blocks of six with a computer-generated list by an unrelated
study person.
2.3. Coronary Angiography. Standard clinical techniques
were used for coronary angiography. A trained interven-
tional cardiologist blinded to all other data interpreted the
angiograms. A coronary diameter stenosis≥ 70% was consid-
ered signiﬁcant. The patients were discussed by the clinical
heart team for standard interventions, and if there were no
further options, the patients were considered for inclusion
in this study.
2.4. Endpoints. The primary outcome was a change in ETT
from baseline to 6 months posttreatment. The statistic
power was estimated to be more than 90% with an enrolment
of 60 patients for detection of an improvement of 60 s
(SD assumed to be 35 s) in the treatment group compared
to the placebo group.
Secondary endpoints were changes in Canadian Car-
diovascular Society (CCS) and New York Heart Association
(NYHA) class, Seattle Angina Questionnaire, weekly use of
nitroglycerin and weekly frequency of angina attacks 3
and 6 months after the treatment, and myocardial perfusion
measured by CT scan at 6 months follow-up.
2.5. Cell Harvesting, Culturing, Expansion, and
Transplantation. Liposuction was performed in local anes-
thesia from the subcutaneous abdominal adipose tissue by
an experienced plastic surgeon. Between 100 and 150mL of
abdominal adipose tissue was obtained. The process of
culturing and expansion of ASCs has been published in
detail previously [20]. The lipoaspirate was washed twice
with phosphate-buﬀered saline (PBS) (Gibco, Life Tech-
nologies) to remove residual blood. The adipose tissue
was digested by collagenase NB6 (Serva GmbH), neutral-
ized with complete medium containing Dulbecco’s modi-
ﬁed Eagle’s medium low glucose 1 g/L (DMEM) (Gibco,
Life Technologies), 1% penicillin/streptomycin (10,000U/
mL and 10.000μg/mL, resp.) (Gibco, Life Technologies),
and 10% fetal bovine serum (FBS) (Gamma irradiated,
Australian origin, Gibco, Life Technologies) according to
a well-established protocol after which the suspension was
ﬁltered (Cell Strainer, BD Falcon), centrifuged, and resus-
pended in complete medium [18]. The isolated SVF was
seeded in 75T culture ﬂasks. The complete medium was
changed every 3-4 days and passaged when they reached
80–90% conﬂuence. The culture-expanded ASCs were stimu-
lated to diﬀerentiate towards endothelial cell linage by
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culturing in VEGF-A165 medium for 7 days before transplan-
tation. The harvested ASCs were suspended in PBS and 0.1%
human albumin in a total volume of 3mL for patients who
received active therapy while PBS and 0.1% human albumin
were mixed with blood from the patient to a total volume
of 3mL for the placebo treatment. This was blinded to the
operator of the intramyocardial injections. The patients
allocated to the ASC group were treated with the full
amount of ASCs reached after two culture expansion pas-
sages. Criteria for release were sterility, viability, and mor-
phology, and the culture media were tested for bacteria,
yeast, and mycoplasma 1 week prior to the treatment
and on the day of treatment. The ASCs were deﬁned
according to criteria established by The International Society
for Cellular Therapy (ISCT).
A 3D electromechanical mapping of the left ventri-
cle endocardium was performed using NOGA® system
(Biologics Delivery Systems, CA, US) to identify viable and
ischemic myocardium. A NOGAMyostar® catheter was used
to deliver 10–15 injections of 0.2mL of ASCs or placebo.
2.6. Cardiac CT Acquisition and Analysis. CT scans were
performed using a 320-multidetector CT scanner (Aquilion
One, Toshiba Medical Systems Corporation, Japan). The
CT protocol and the measured parameters have been
described in details previously [21, 22]. First, scout images
were acquired to localize the heart. Then, rest perfusion
images were acquired. Images were acquired from above
the origin of the coronary arteries to the diaphragm. Finally,
adenosine stress perfusion images were acquired.
Images were reconstructed with 0.5mm slice thickness
and increments of 0.25mm in 2% interval in the prospective
window and transferred to a workstation (Vitrea 6.2 Vital
Images Inc., Minnetonka, Minnesota, USA) for analysis.
Attenuation density (AD), perfusion index (PI), and
transmural perfusion ratio (TPR) were obtained and used
for the semiquantitative analysis after semiautomatically
tracing of endo- and epicardial borders of the myocar-
dium. The PI was calculated as the ratio between the myo-
cardial AD divided by AD in the left ventricle blood pool
while TPR was calculated as the ratio of AD between
endo- and epicardium.
Moreover, left ventricle end-diastolic volume, left ventri-
cle thickness, and left ventricle muscle mass were obtained
for further analysis.
2.7. Statistics. SPSS version 23.0 (SPSS Inc., Chicago, Illinois)
was used for data analysis. Continuous variables are pre-
sented as mean± standard deviation (SD) or 95% conﬁdence
interval and categorical variables are presented as numbers
and percentages. Paired t-test is used for comparison of
continuous data within groups while unpaired t-test is used
49 excluded
49 did not meet inclusion criteria 
10 consent withdrawn
1 dead
1 limited abdominal tissue
Signed consent (n = 110)
Randomization (n = 61)
ASC (n = 41)
Endocardial NOGA mapping (n = 41)
Intramyocardial injections of ASC (n = 40)
1 month follow-up (n = 38)
3 months follow-up (n = 37)
1 myocardial infarction, no
intervention
1 outside country
1 dead
1 pericardial effusion after
stem cell injections
1 pericardial effusion,
consent withdrawn
Placebo (n = 20)
Endocardial NOGA mapping (n = 20)
Intramyocardial injections of placebo (n = 20)
1 month follow-up (n = 20)
1 myocardial infarction,
coronary intervention
3 months follow-up (n = 19)
6 months follow-up (n = 19) 6 months follow-up (n = 37)
Figure 1: Study design. Eligibility, randomization into adipose-derived stromal cell (ASC) or placebo group, and follow-up.
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for comparison between groups. Repeated measure with
autoregressive covariance structure is used for follow-up
data with more than two time-points (bicycle ETT, symp-
toms, angina attacks, use of short-term nitroglycerin, and
Seattle Angina Questionnaire). The data were analyzed as
intention-to-treat analysis with patients present at follow-
up. Categorical data were compared using Fisher’s exact test.
A two-tailed probability value< 0.05 was considered to indi-
cate statistical signiﬁcance.
3. Results
Sixty-one patients were randomized and sixty patients
were treated with either ASCs or placebo (Figure 1). One
Table 1: Baseline characteristics.
Parameter Placebo (n = 20) ASC (n = 40) P value
Age (years) 65.3± 8.7 65.5± 9.7 0.94
Male gender 20 (100) 35 (87.5) 0.02
BMI (kg/m2) 30.0± 4.8 30.0± 4.1 0.92
Smoking 0.19
Current 3 (15) 8 (20)
Previous 16 (80) 23 (57.5)
Never 1 (5) 9 (22.5)
Diabetes mellitus 6 (30) 16 (40) 0.57
Hypertension 12 (60) 33 (82.5) 0.06
AMI 10 (50) 26 (65) 0.26
CABG 20 (100) 33 (82.5) 0.08
PCI 15 (75) 28 (70) 0.69
LVEF (%) 54± 8 52± 8 0.38
Systolic blood pressure (mmHg) 133± 19 132± 17 0.91
Diastolic blood pressure (mmHg) 76± 11 76± 12 0.99
Heart rate (beats/min) 66± 9 63± 7 0.14
FEV1 (L) 2.27± 0.61 2.34± 0.69 0.69
FVC (L) 3.17± 0.65 3.11± 0.80 0.76
FEV1/FVC 71.2± 10.3 74.8± 7.7 0.18
Pro-BNP (pmol/L) 30.4± 24.3 39.6± 37.5 0.27
TnT (ng/L) 12.5± 2.1 14.9± 7.8 0.09
CK-MB (μg/L) 2.8± 1.6 3.2± 1.4 0.36
Hgb A1c (mmol/L) 6.1± 0.6 6.7± 1.3 0.03
Total cholesterol (mmol/L) 3.8± 0.7 4.3± 1.2 0.06
HDL-C (mmol/L) 1.0± 0.2 1.2± 0.4 0.05
LDL-C (mmol/L) 1.9± 0.6 2.5± 1.0 0.02
Triglycerides (mmol/L) 2.6± 1.5 1.8± 0.8 0.06
CRP (mg/L) 5.0± 10.0 3.6± 3.7 0.57
Medication
Acetylsalicylic acid 19 (95) 35 (87.5) 0.65
Clopidogrel 7 (35) 11 (27.5) 0.56
ACE-I or ARB 13 (65) 29 (72.5) 0.42
β-Blocker 16 (80) 33 (82.5) 1.00
Calcium antagonist 12 (60) 19 (47.5) 0.42
Diuretics 12 (60) 27 (67.5) 0.58
Statins 20 (100) 40 (100) 1.00
Nitrate 19 (95) 28 (70) 0.04
Nicorandil 6 (30) 5 (12.5) 0.16
Ivabradine 2 (10) 4 (10) 1.00
ACE-I: angiotensin-converting enzyme inhibitor; AMI: acute myocardial infarction; ARB: angiotensin II receptor blockers; ASC: adipose-derived stromal cell;
BMI: body mass index; CABG: coronary artery bypass grafting; CK-MB: creatine kinase MB; CRP: C-reactive protein; FEV1: forced expiratory volume in 1 s;
FVC: forced vital capacity; HDL-C: high-density lipoprotein cholesterol; Hgb A1c: hemoglobin A1c; LDL: low-density lipoprotein cholesterol; LVEF: left
ventricular ejection fraction; n: number of patients; PCI: percutaneous coronary intervention; Pro-BNP: probrain natriuretic peptide; TnT: troponin T.
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patient did not show up for 3 months follow-up due to vaca-
tion outside the country but returned to attend the 6 months
follow-up. Baseline characteristics are shown in Table 1. All
patients had previously undergone percutaneous coronary
intervention and/or coronary artery bypass grafting. The
medication was kept unchanged during the 6 months
follow-up period.
The abdominal liposuction volume resulted in 94 ±
25mL (mean ± SD). The isolated stromal vascular fraction
amounted to 94 ± 61× 106 cells (mean ± SD). The cells were
culture expanded for two passages under good manufactur-
ing practice conditions for 32 ± 14 days (mean ± SD) which
resulted in 72.0 ± 44.9× 106 ASCs (mean ± SD) having nor-
mal morphology. The cell viability was 89 ± 5% (mean ±
SD), and there was no contamination with bacteria, yeast,
or mycoplasma.
3.1. Serious Adverse Events. One patient had a pericardial
eﬀusion during NOGAmapping. The procedure was stopped
before injection of stem cells and the patient was treated with
pericardiocentesis and withdrew consent. Another patient
had pericardial eﬀusion after stem cell injections. The patient
was treated with surgical intervention. Both recovered with-
out any sequela.
One patient from the ASC group died before 1-month
follow-up due to sudden cardiac arrest. One patient from
the ASC group had a transient sinoatrial block, and two
patients (ASC and placebo group) had transient nonsus-
tained ventricular tachycardia related to the NOGA proce-
dure. One ASC-treated patient had an allergic reaction
observed after the NOGA procedure with rash and fever. In
all cases, there were no needs for any treatment. Two patients
(from ASC and placebo group) had acute myocardial infarc-
tion during 6 months of follow-up. There were no statistical
signiﬁcant diﬀerences between the groups (Table 2). No
patient had more than 1 event. Figure S1 shows the serial
levels of troponin T and CKMB.
3.2. Exercise Tolerance Testing. The primary endpoint,
changes in ETT from baseline to follow-up, was increased
in the placebo group 9 s (95% CI –203 to 221 s) and in the
ASC group 22 s (95% CI –164 to 208 s). However, there was
no statistical signiﬁcant diﬀerence between the groups (P =
0 680) (Figure 2(a)). The mean bicycle ETT duration at base-
line was 437 ± 53 s and 383 ± 30 s (P = 0 053) for the placebo
and ASC groups, respectively. At 6 months follow-up, the
ETT duration of time increased to 446 ± 64 s and 407 ± 36 s
in placebo group and ASC group, respectively. The increase
in time duration, from baseline to follow-up, was only signif-
icant in the ASC group (P = 0 034) (Figure 3(a)).
There was no diﬀerence between the two groups
for change in watt from baseline to 6 months follow-up
(7 (95% CI –40 to 54) watt and 4 (95% CI –33 to 41) watt;
P = 0 608 for the placebo group and for the ASC group, resp.)
(Figure 2(b)). The ASC group performed 81 ± 6 watts at base-
line which increased signiﬁcantly to 85 ± 8 watts at 6 months
follow-up (P = 0 048). There was no signiﬁcant change in the
placebo group (87 ± 12 watts at baseline and 94 ± 13 watts at
6 months follow-up, P = 0 41) (Figure 3(b)).
The metabolic equivalents (METs) performed by the
patients in the ASC group did also increase signiﬁcantly
from 4.2 ± 0.3 at baseline to 4.4 ± 0.3 at 6 months follow-up
(P = 0 048), while it was unchanged in the placebo group
(4.5 ± 0.4 at baseline and 4.6 ± 0.5 at follow-up, P = 0 757)
(Figure 3(c)). However, there was no diﬀerence between the
two groups for change in METs from baseline to 6 months
follow-up (0.1 (95% CI –1.7 to 1.9) and 0.2 (95% CI –1.4 to
1.8); P = 0 720 for the placebo group and for the ASC group,
resp.) (Figure 2(c)).
3.3. Symptoms and Antianginal Medication. All patients had
at least CCS class II and/or angina-equivalent dyspnea
NYHA class II at baseline. During the 6-month follow-up
time, there was a signiﬁcant decrease in CCS class for patients
both in the placebo and ASC group, P = 0 037 and P < 0 001,
respectively (Figure 4(a)). There was a similar decrease in
NYHA class for placebo and ASC groups, P = 0 043 and
P = 0 001, respectively (Figure 4(b)).
There was a signiﬁcant decrease in weekly angina
attacks for both the patients in the placebo and ASC groups
(P = 0 032 and P = 0 002, resp.) (Figure S2A). However, the
Table 2: (a) Serious adverse events after NOGA mapping and
injections in the placebo and adipose-derived stromal cell (ASC)
group. (b) Number of patients with one or more SAE/AE(s) in
patients treated with placebo or ASCs.
(a)
Serious adverse events
Placebo
(n = 20)
ASC
(n = 40) P value
Death 0 (0) 1 (2.5) 1.00
Hospitalizations
Myocardial infarction 1 (5) 1 (2.5) 1.00
Dyspnea 0 (0) 1 (2.5) 1.00
Anemia 1 (5) 1 (2.5) 1.00
Syncope 1 (5) 0 (0) 0.33
Peripheral edema 0 (0) 1 (2.5) 1.00
Angina worsening 3 (15) 6 (15) 1.00
Pneumonia 1 (5) 1 (2.5) 1.00
NOGA-related complications
Pericardial eﬀusion 0 (0) 1 (2.5) 1.00
ECG changes—SA-block, NsVT 2 (10) 1 (2.5) 0.26
Hematoma at femoral puncture 1 (5) 0 (0) 0.33
Allergic reaction 0 (0) 1 (2.5) 1.00
Bradycardia 0 (0) 1 (2.5) 1.00
General discomfort 0 (0) 1 (2.5) 1.00
NsVT: nonsustained ventricular tachycardia; SA-block: sinoatrial block.
Values are n (%); P values are calculated using Fischer’s exact test.
(b)
Placebo
(n = 20)
ASC
(n = 40) P value
Major adverse events 4 (20) 9 (22.5) 1.00
Nonmajor adverse events 4 (20) 4 (10) 0.42
Values are n (%); P values are calculated using Fischer’s exact test.
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use of short-term nitroglycerin was not signiﬁcantly reduced
in any of the groups (Figure S2B).
3.4. Seattle Angina Questionnaire. There was a signiﬁcant
improved angina stability score, angina frequency score,
quality-of-life, and physical limitation score in both
groups (Figure S3). Nevertheless, there was no change
in overall satisfaction score in the groups. No signiﬁcant dif-
ferences between the two groups were observed for Seattle
Angina Questionnaire.
3.5. CT Perfusion Images and Functional Analysis. All
patients underwent rest CT scan and 54 patients went
through stress CT scan at baseline. At 6 months follow-
up, 56 patients underwent rest CT scan while 49 patients
had a stress CT scan performed. There were no diﬀerences
between the groups for global attenuation density (AD),
perfusion index (PI), or transmural perfusion ratio (TPR)
(Table 3(a)). Additionally, there were no signiﬁcant
diﬀerences between the two groups in AD, PI, or TPR
related to the coronary territories where the injections
were performed. Moreover, there were no diﬀerences for
left ventricle end-diastolic volume, left ventricle thickness,
or left ventricle muscle mass (Table 3(b)).
4. Discussion
MystromalCell trial is the ﬁrst-in-man randomized, double-
blind placebo-controlled study using VEGF-A165-stimulated
culture-expanded ASCs for patients with refractory angina
due to CIHD and preserved LVEF. There were no statisti-
cal signiﬁcant diﬀerences between the groups for the pri-
mary endpoint, change in the bicycle exercise tolerance
test, from baseline to 6 months follow-up. However, there
was a signiﬁcant increase in bicycle exercise tolerance test in
time duration and work capacity in patients receiving ASCs,
which was not seen in the placebo group. A signiﬁcant
improvement in CCS class and NYHA class in the ASC and
P = 0.680
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Figure 2: Bicycle exercise test. Between-group comparison of primary endpoint (a) time duration, (b) watt, and (c) metabolic equivalents
(METs) of changes from baseline to 6 months follow-up (values are mean ± 95% conﬁdence interval).
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placebo group was also observed. Furthermore, there was a
signiﬁcant decrease in weekly angina attacks and improved
quality-of-life score in both groups.
The aim of this study was to improve exercise capacity
due to increased myocardial perfusion induced by VEGF-
A165-stimulated ASCs. Using static CT perfusion analysis,
we did not detect any signiﬁcant change in global myocardial
perfusion during rest or pharmacological stress. Although
rest and stress AD decreased slightly from baseline to
follow-up in the placebo group and remained unchanged in
the ASC group, the changes may have been too small to be
detected by CT on either global or vessel territorial level or
the analysis method may need to be optimized. Furthermore,
this imaging method is not designed to register absolute
changes in microvascular perfusion but only relative changes.
Another treatment method for improvement of myocar-
dial perfusion using transmyocardial laser revascularization
has been tested in several clinical trials but without any clear
eﬀect [23]. However, we cannot exclude that the intramyo-
cardial injections by itself improve the myocardial perfusion
independently of the stem cells.
The ﬁnding that the weekly use of nitroglycerin was
unchanged while weekly angina attacks decreased along with
an increasing angina frequency score is an indication of
increasing health status and therefore in accordance with
the improved clinical status observed.
The improvement in exercise tolerance and in angina
observed in this study is consistent with the previous pub-
lished reports using exercise test as an outcome measure after
CD34+ treatment in patients with refractory angina [24, 25]
while another study showed a greater increase in exercise
time than observed in this study [26]. These studies might
have used diﬀerent protocols so a direct comparison of the
exercise tolerance has to be done carefully. However, with a
2 : 1 ratio and the present population size, we cannot reject
a type 2 error in this study.
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Figure 3: Bicycle exercise test. Primary endpoint (a) time duration, (b) watt, and (c) metabolic equivalents (METs) at baseline, 3, and
6 months follow-up for placebo group and patients treated with adipose-derived stromal cells (ASCs) (values are mean ± 95%
conﬁdence interval).
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Preclinical studies have previously demonstrated the
beneﬁt of intramyocardial injection of ASCs. In mice with
CIHD, ASC improved LVEF assessed by echocardiography
and 18F-FDG microPET imaging [27]. Moreover, intramyo-
cardially injected ASCs have demonstrated increased LVEF,
wall thickness, and reduction of infarct size in rats [28].
A small study using an intramyocardial injection of
freshly harvested adipose-derived SVF cells in patients with
refractory angina showed that exercise capacity measured
as METs in the active group remained stable while there
was a decrease in METs in the placebo group [9]. Another
small study delivering freshly harvested adipose-derived
SVF cells intracoronary in patients with ST-elevation myo-
cardial infarction showed a trend towards improved LVEF
[19]. The Athena trials used an intramyocardial injection of
adipose-derived SVF cells in patients with ischemic heart
failure and showed that maximum oxygen consumption on
exercise treadmill testing was increased in the therapy group
but not signiﬁcantly diﬀerent from the placebo group [8].
Used SVF cell populations are however heterogeneous,
compromising approximately 2% ASCs [29]. To achieve suf-
ﬁcient numbers of SVF eﬀector cells for treatment without
culture expansion, 2-3 times the amount of fat tissue has to
be harvested from the patients [8].
A change in paradigm has occurred in the understanding
of the regenerative mechanisms of ASCs since the initiation
of MyStromalCell. As such, the decisive factor for the regen-
erative capacity of ASCs is now believed to be of paracrine
nature, and therefore, an angiogeneic prestimulation proto-
col as of the present is potentially not needed [29].
The ADVANCE study was a phase II double-blinded
safety trial in Europe which planned to enroll 360 patients
with acute myocardial infarction to be randomized either to
intracoronary delivered freshly harvested adipose-derived
SVF cells or placebo. The preliminary data showed the safety
of the treatment and the study group terminated the trial
before full enrolment [30].
Previously, bone marrow-derived MSCs have shown to
reduce symptoms of patients with CIHD with and without
heart failure [10, 12, 13].
In 50 patients with CIHD randomized to either
intramyocardial injections of bone marrow-derived mono-
nuclear cells or placebo, cell therapy demonstrated
improved myocardial perfusion assessed by single-photon
emission computed tomography 3 months after the treat-
ment [31].
A signiﬁcant diﬀerence between the active and the pla-
cebo groups in the primary endpoint, changes in ETT from
baseline to follow-up between the groups, was not reached.
The power calculation prior to the study start estimated a dif-
ference in time duration between the groups of 60 s [20].
However, the diﬀerence in time duration was less than half
of the expected amount. A power calculation with the present
standard deviation of 24 s, a power of 90%, and a randomiza-
tion ratio of 2 : 1 with a signiﬁcance level of 5% indicates that
twice the patient population included into this study is
needed to detect the observed diﬀerence in the change of time
between the two groups. Probably, the number of enrolled
patients has to be even higher due to patient dropout, death,
withdrawal of consent, and so forth. Moreover, an increase of
at least 0.5 METs may be of value for the patient [32]. In
upcoming randomized trials, a combined endpoint could be
a more suitable endpoint.
The patients were referred from other hospitals and
coronary angiography databases were looked through to
ﬁnd potential candidates to be included into this study.
However, these no-option patients may be more diﬃcult
to ﬁnd today since new techniques for interventions on
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chronic total coronary occlusions and so forth are now
more widely implemented.
Most clinical studies as of the present use autologous
stem cells. However, with this design, it is diﬃcult to stan-
dardize the treatment. The ASCs have to be culture expanded
for several weeks and the number and quality of cells reached
for treatment vary considerably from patient to patient. This
could potentially have had an impact on the eﬀect of the ther-
apy in this study. With newly established cell culture
methods using closed bioreactor systems and optimized cul-
tivation media, a much higher cell yield can be reached [33].
Therefore, it can be speculated whether this technology and a
standardized allogeneic stem cell product from healthy
donors together with a higher cell number for treatment
would have had improved the clinical outcome.
Preconditioning or genetically modifying the stem cells,
before transplantation, may play a role and have to be inves-
tigated further. Moreover, one injection or multiple injec-
tions, route of cell delivery, the optimal cell source, and the
process during culture expansion are some of the steps,
which may have importance for the eventual eﬀect. How-
ever, we still need larger studies and international multicen-
ter studies, such as the SCIENCE trial (NCT02673164),
which may be the next step forward in order to establish
stem cell therapy as a daily practice therapy outside con-
trolled trials. At the moment, stem cell therapy should
only be performed in controlled trials. Nevertheless, the
present study is still an important report due to the safety
and feasibility demonstration. It should be emphasized
that myocardial perforation caused by the NOGA mapping
procedure and the intramyocardial injections calls for
highly experienced operators to minimize the risk of this
serious complication.
Compared to conventional medical and interventional
therapy, cell-based therapies have the potential to regenerate
the ischemic myocardium [34]. However, based on the pres-
ent and previous results, it can be concluded that to detect a
signiﬁcant diﬀerence in exercise tolerance between the pla-
cebo and the present used stem cell, several hundreds of
patients have to be enrolled [35].
Limitations of the study are that at the baseline; the
exercise time duration is seemingly better in the placebo
group compared to the ASC group and the changes seem
like they are increasing constantly. Some of the patients
were lost to follow-up, and there was an imbalance in some
of the measurements between the groups. Moreover, the
observed eﬀect sizes were smaller than probably clinical
relevant and the groups are relatively small. The increased
performance on bicycle ETT could be due to the fact that the
patients got used to performing the test. It will be interesting
in the future to follow these patients to observe how their
symptoms and work capacity changes and whether the
placebo eﬀect disappears.
In conclusion, this double-blind placebo-controlled study
using VEGF-A165-stimulated culture-expanded autologous
ASCs demonstrates that the treatment was safe but did not
show a diﬀerence between the groups in the primary end-
point ETT. However, there was an increase in the ASC group
for the ETT, which was not seen in the placebo group.
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Appendix
A. Inclusion criteria
(i) Age between 30 and 80 years
(ii) Moderate to severe angina (CCS angina classes II-
III) or angina equivalent dyspnea (NYHA classes
II-III) despite optimal medical therapy
(iii) Must have, within 12 months prior to entry, docu-
mented coronary angiographic evidence of signiﬁ-
cant vessel disease and at least one remaining
larger coronary vessel from which new collaterals/
vessels could be supplied
(iv) Must not be eligible for any other revascularization
procedures
(v) Left ventricular ejection fraction> 40% measured
by echocardiography, SPECT, CT-scan, or MRI
(vi) Duration of bicycle ergometry exercise tolerance
tests: 2 to 10 minutes
(vii) CABG or PCI within 6 months of entry must have
angiography performed at least 4 months after the
previous intervention to rule out early restenosis
and to document remaining signiﬁcant vessel
disease
(viii) Ventricular wall thickness of the treatment
zone> 7mm measured by echocardiography, CT-
scan, or MRI
Note. CABG: coronary artery bypass grafting; CCS:
Canadian Cardiovascular Society; CT: computed tomogra-
phy; MRI: magnetic resonance imaging; NYHA: New York
Heart Association; PCI: percutaneous coronary intervention;
SPECT: single-photon emission computed tomography.
B. Exclusion criteria
(i) Pregnant or lactating women
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(ii) Clinically signiﬁcant anemia, leukopenia, leukocy-
tosis, or thrombocytopenia
(iii) Conditions other than angina that will limit exer-
cise test (e.g., severe peripheral vascular disease,
COPD, and FEV1< 1)
(iv) Immunocompromised status or currently receiving
immunosuppressive therapy
(v) Valvular heart disease requiring surgical
intervention
(vi) Less than 6 weeks prior to screening: ACS with
increase in CK-MB or troponins/PCI/CABG/
stroke or TIA
(vii) History of malignancy< 5 years (except cured non-
melanoma skin cancer) or suspicion of current
malignancy
(viii) Other experimental medications within the last
four weeks prior to the baseline ETT
Note. ACS: acute coronary syndrome; CABG: coronary
artery bypass grafting; COPD: chronic obstructive pulmo-
nary disease; ETT: exercise tolerance test; FEV1: forced expi-
ratory volume in one second; PCI: percutaneous coronary
intervention; TIA: transient ischemic attack.
Supplementary Materials
Figure S1: TNT and CKMB levels before and after treatment:
(A) TNT and (B) CKMB. (Boxed values are mean± 95%
conﬁdence interval.) Figure S2: Weekly (A) angina attacks
and (B) use of short-term nitroglycerin (NTG). (Values are
mean± 95% conﬁdence interval.) Figure S3: Seattle Angina
Questionnaires. The (A) angina stability score, (B) angina
frequency score, (C) quality of life score, (D) physical
limitation score, and (E) satisfaction score (Values are
mean± 95% conﬁdence interval.) (Supplementary materials)
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